Canaccord Genuity reiterated a Buy rating and $85.00 price target on Radius Health (NASDAQ: RDUS) after presenting new transdermal data at ASBMR.

Analyst John Newman commented, "Radius presented new transdermal data at ASBMR in monkeys, which increased AUC ~2x versus the original patch, and retained rapid delivery and Cmax comparable to the subcutansous formulation, suggesting human studies will be successful. Photographs of the transdermal poster were not permitted at ASBMR without ejection from the meeting, so we await further details going forward."

For an analyst ratings summary and ratings history on Radius Health click here. For more ratings news on Radius Health click here.

Shares of Radius Health closed at $57.80 yesterday.